[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"epstein-barr-virus-associated-lymphoproliferative-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:epstein-barr-virus-associated-lymphoproliferative-disorders":46},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100627573",false,"NCT07450391","EBV-AST Cell Injection for EBV-Associated Lymphoproliferative Disorders","Exploratory Clinical Study of EBV-AST Cell Injection for the Treatment of EBV-Associated Lymphoproliferative Disorders","Inclusion Criteria:\n\n1. Able to understand and voluntarily sign written informed consent.\n2. Age 18 to 75 years, inclusive.\n3. HLA genotype matches at least one of the following: HLA-A02:01, HLA-A11:01, or HLA-A\\*24:02.\n4. Karnofsky Performance Status (KPS) ≥ 70.\n5. Life expectancy ≥ 3 months.\n6. Diagnosed with EBV-associated lymphoproliferative disorders, including:\n7. EBV infection-associated post-transplant lymphoproliferative disorder (PTLD) that is relapsed\u002Frefractory after at least first-line standard therapy; or\n8. EBV-associated lymphoma confirmed by histology and\u002For cytology with EBER positivity (ISH\u002FFISH), with no standard treatment available or not suitable for standard therapy, including but not limited to: EBV-positive DLBCL, EBV-positive NK\u002FT-cell lymphoma, EBV-positive Hodgkin lymphoma, EBV-positive Burkitt lymphoma, EBV-positive nodal TFH lymphoma (AITL type), and EBV-positive primary cutaneous T-cell lymphoma, meeting protocol-defined relapsed\u002Frefractory criteria.\n9. Absolute lymphocyte count ≥ 0.8 × 10\\^9\u002FL (except for PTLD participants).\n10. Adequate organ and bone marrow function per protocol-defined criteria.\n11. Participants of childbearing potential agree to use highly effective contraception throughout the study; women of childbearing potential must have a negative pregnancy test at screening.\n\nExclusion Criteria:\n\n1. Known hypersensitivity to the investigational product or its components.\n2. Uncontrolled active graft-versus-host disease (GVHD) in PTLD participants.\n3. Known primary immunodeficiency disorders (e.g., X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, chronic granulomatous disease, hyper-IgE syndrome).\n4. Severe uncontrolled medical conditions that, in the investigator's judgment, make the participant unsuitable for enrollment.\n5. Serious cardiac disease within 6 months prior to first infusion (e.g., myocardial infarction, severe\u002Funstable angina, bypass surgery, NYHA class III-IV heart failure).\n6. Chronic diseases requiring systemic immunosuppressants or systemic steroids (except local\u002Finhaled steroids or physiologic replacement therapy).\n7. History of other malignancy within the past 5 years, except carcinoma in situ (e.g., cervix, bladder, breast) or non-melanoma skin cancer.\n8. Receipt of lymphocyte-based immunotherapy (e.g., CIK, DC, DC-CIK, LAK) within 3 months prior to consent.\n9. Receipt of interferon or other targeted immunodeficiency drugs within 3 months prior to consent; prior high-dose IL-2 therapy.\n10. Anti-cancer therapy within 14 days prior to consent (including chemotherapy or immunosuppressants\u002Fsteroids); other cell therapy or live vaccines\u002Fattenuated vaccines or other investigational drugs within 28 days prior to consent; curative radiotherapy or major surgery within 4 weeks, or palliative local radiotherapy within 2 weeks prior to consent.\n11. Prior immune therapy-associated ≥ Grade 3 immune-related adverse events (irAEs).\n12. Unresolved toxicity from prior therapy \\> Grade 1 (except alopecia any grade; peripheral sensory neuropathy ≤ Grade 2).\n13. Uncontrolled psychiatric or neurologic disorders; drug abuse or alcohol dependence.\n14. Positive HIV antibody; positive Treponema pallidum antibody; active hepatitis B (HBsAg and\u002For HBeAg positive with HBV-DNA above ULN) or active hepatitis C (HCV-Ab positive and HCV-RNA positive).\n15. Uncontrolled severe active infection or contagious disease (excluding EBV infection).\n16. Pregnant or breastfeeding women.","ALL","18 Years","70 Years",{"count":19,"type":20},18,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","This is an investigator-initiated, open-label, single-arm, dose-escalation exploratory study to evaluate the safety, tolerability, and preliminary efficacy of EBV-AST cell injection in adults with EBV-associated lymphoproliferative disorders, including post-transplant lymphoproliferative disease (PTLD) and EBV-positive lymphomas. Participants will receive EBV-AST cell infusions intravenously every 2 weeks for up to 3 infusions at escalating dose levels. The primary objective is to assess safety and determine a potential optimal biologically active dose. Secondary objectives include preliminary tumor response and EBV-related virologic outcomes, as well as cellular PK\u002FPD.",[27,28],"Epstein-Barr Virus-Associated Lymphoproliferative Disorders","EBV-Positive Lymphoma",[30,31,32,33],"EBV-associated lymphoproliferative disorder","EBV-positive lymphoma","Adoptive T-cell therapy","Antigen-specific T cells","RECRUITING","2026-02-26",{"date":37,"type":38},"2026-03-04","ACTUAL",{"date":40,"type":38},"2025-06-01",{"date":42,"type":20},"2027-06-01",{"name":44,"class":45},"Daihong Liu","OTHER",""]